Current status of amyloid-targeting immunotherapies for Alzheimer's disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37939161.
- Also identified by DOI 10.1126/scitranslmed.adk9993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer's disease.
Medical subject headings
- Alzheimer Disease